Fan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fan Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Maosheng Xu
Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
5 shared publications Feini Zhou
The First School of Clinical Medicine of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China
3 shared publications- Hao Jiang
The First School of Clinical Medicine of Zhejiang Chinese Medical University
3 shared publications Lingnan Guo
The First School of Clinical Medicine of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China
3 shared publications- Feini Zhou
The First School of Clinical Medicine of Zhejiang Chinese Medical University
2 shared publications - Haitao Chen
Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province
2 shared publications
Latest Publications
- Open Access
- 10 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115845
CDP-choline modulates cholinergic signaling and gut microbiota to alleviate DSS-induced inflammatory bowel disease
- 10 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115845
Open AccessCDP-choline modulates cholinergic signaling and gut microbiota to alleviate DSS-induced inflammatory bowel disease
- Open Access
- 19 January 2023
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2023, 1-21
Electroacupuncture Alleviates 46-Trinitrobenzene Sulfonic Acid-Induced Visceral Pain via the Glutamatergic Pathway in the Prefrontal Cortex
Visceral pain caused by inflammatory bowel disease (IBD) greatly diminishes the quality of life in affected patients. Yet, the mechanism of how IBD causes visceral pain is currently not fully understood. Previous studies have suggested that the central nervous system (CNS) and gut-brain axis (GBA) play an important role in IBD-inducing visceral pain. As one of the treatments for IBD, electroacupuncture (EA) has been used to treat various types of pain and gastrointestinal diseases in clinical practice. However, whether EA relieves the visceral pain of IBD through the gut-brain axis has not been confirmed. To verify the relationship between visceral pain and CNS, the following experiments were conducted. 1H-NMR analysis was performed on the prefrontal cortex (PFC) tissue obtained from IBD rat models to determine the link between the metabolites and their role in EA treatment against visceral pain. Western blot assay was employed for detecting the contents of glutamate transporter excitatory amino acid transporters 2 (EAAT2) and the glutamate receptor N-methyl-D-aspartate (NMDA) to verify whether EA treatment can alleviate neurotoxic symptoms induced by abnormal increases of glutamate. Study results showed that the glutamate content was significantly increased in the PFC of TNBS-induced IBD rats. This change was reversed after EA treatment. This process was associated with increased EAAT2 expression and decreased expression of NMDA receptors in the PFC. In addition, an increase in intestinal glutamic-metabolizing bacteria was observed. In conclusion, this study suggests that EA treatment can relieve visceral pain by reducing glutamine toxicity in the PFC, and serves an alternative clinical utility.
- 19 January 2023
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2023, 1-21
Open AccessElectroacupuncture Alleviates 46-Trinitrobenzene Sulfonic Acid-Induced Visceral Pain via the Glutamatergic Pathway in the Prefrontal Cortex
Visceral pain caused by inflammatory bowel disease (IBD) greatly diminishes the quality of life in affected patients. Yet, the mechanism of how IBD causes visceral pain is currently not fully understood. Previous studies have suggested that the central nervous system (CNS) and gut-brain axis (GBA) play an important role in IBD-inducing visceral pain. As one of the treatments for IBD, electroacupuncture (EA) has been used to treat various types of pain and gastrointestinal diseases in clinical practice. However, whether EA relieves the visceral pain of IBD through the gut-brain axis has not been confirmed. To verify the relationship between visceral pain and CNS, the following experiments were conducted. 1H-NMR analysis was performed on the prefrontal cortex (PFC) tissue obtained from IBD rat models to determine the link between the metabolites and their role in EA treatment against visceral pain. Western blot assay was employed for detecting the contents of glutamate transporter excitatory amino acid transporters 2 (EAAT2) and the glutamate receptor N-methyl-D-aspartate (NMDA) to verify whether EA treatment can alleviate neurotoxic symptoms induced by abnormal increases of glutamate. Study results showed that the glutamate content was significantly increased in the PFC of TNBS-induced IBD rats. This change was reversed after EA treatment. This process was associated with increased EAAT2 expression and decreased expression of NMDA receptors in the PFC. In addition, an increase in intestinal glutamic-metabolizing bacteria was observed. In conclusion, this study suggests that EA treatment can relieve visceral pain by reducing glutamine toxicity in the PFC, and serves an alternative clinical utility.
- Open Access
- 5 December 2022
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 6569-6580
Lipidomics Changes in a Murine Model of Neuropsychiatric Lupus
Purpose: Neuropsychiatric lupus (NPSLE) is one of the important manifestations of systemic lupus erythematosus. Previous studies mainly focused on the disruption of the blood-brain barrier and the production of brain-reactive autoantibodies, However, there is no comprehensive lipidomic analysis in NPSLE. Therefore, this research evaluated the lipidomic analysis in the hippocampus and liver of NPSLE mice with mood disorders, to explore the influence of the liver-brain axis on this disease. Methods: MRL/lpr mice and MRL/mpj mice were respectively used as NPSLE and control groups. Behavioral tests and systemic disease characteristics of mice were assessed at the age of 18 weeks. Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) was used for lipid metabolite determination. Multivariate statistical analysis was used to identify lipid metabolites that were differentially expressed in two groups. Results: Our results showed that 355 and 405 lipid metabolites were differentially expressed between the NPSLE and control groups in the hippocampus and liver. According to the pathway enrichment analysis, several pathways were affected, and the glycerophospholipid metabolism pathway was most relevant to the mouse’s depressive behavior. Conclusion: Based on UPLC-MS/MS, the results provide evidence for how the liver-brain axis affects NPSLE and improve the understanding of NPSLE pathogenesis.
- 5 December 2022
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 6569-6580
Open AccessLipidomics Changes in a Murine Model of Neuropsychiatric Lupus
Purpose: Neuropsychiatric lupus (NPSLE) is one of the important manifestations of systemic lupus erythematosus. Previous studies mainly focused on the disruption of the blood-brain barrier and the production of brain-reactive autoantibodies, However, there is no comprehensive lipidomic analysis in NPSLE. Therefore, this research evaluated the lipidomic analysis in the hippocampus and liver of NPSLE mice with mood disorders, to explore the influence of the liver-brain axis on this disease. Methods: MRL/lpr mice and MRL/mpj mice were respectively used as NPSLE and control groups. Behavioral tests and systemic disease characteristics of mice were assessed at the age of 18 weeks. Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) was used for lipid metabolite determination. Multivariate statistical analysis was used to identify lipid metabolites that were differentially expressed in two groups. Results: Our results showed that 355 and 405 lipid metabolites were differentially expressed between the NPSLE and control groups in the hippocampus and liver. According to the pathway enrichment analysis, several pathways were affected, and the glycerophospholipid metabolism pathway was most relevant to the mouse’s depressive behavior. Conclusion: Based on UPLC-MS/MS, the results provide evidence for how the liver-brain axis affects NPSLE and improve the understanding of NPSLE pathogenesis.
- Open Access
- 14 November 2022
- Published by Springer Nature in Research Square
Choline deficiency and choline metabolism disorders can lead to anxiety-like behaviors induced by DSS in IBD mice
Anxiety and depression caused by inflammatory bowel diseases (IBD) negatively affect the mental health of patients. Emerging studies have demonstrated that the gut-brain axis mediates IBD-induced mood disorders, but the underlying mechanisms of these findings remain unknown. This study unveiled promising evidence that choline dysfunction may be a cause of IBD induced mood disorders. Analysing Dextran Sulfate Sodium Salt (DSS)-induced IBD mice model with transcriptomics and metabolomics technology, it was discovered that mRNA responsible for acetylcholine synthesis and secretion were increased and the phosphatidylcholine (PC) content were decreased in prefrontal cortex (PFC) of IBD mice compared to the Control. Fecal Metagenomics showed that the microbiome and lipid metabolism were also abnormal in IBD mice. Since both acetylcholine and PC are choline metabolites, we inferred that the IBD mice may suffer from choline deficiency and choline metabolism disorder. Following supplementation of CDP-choline, experimental subjects showed improvements through decreased anxiety-like behaviors, reduced PC degradation and increased acetylcholine synthesis in the PFC. In addition, CDP-choline treatment was shown to restore the gut microbiome and lipid metabolism disorders characteristic of DSS treatment. This study provides compelling evidence to suggest that choline metabolism plays a key role in the development and treatment of mood disorders in IBD patients, and choline and its metabolites may play a key role in maintaining the stability of the gut-brain axis.
- 14 November 2022
- Published by Springer Nature in Research Square
Open AccessCholine deficiency and choline metabolism disorders can lead to anxiety-like behaviors induced by DSS in IBD mice
Anxiety and depression caused by inflammatory bowel diseases (IBD) negatively affect the mental health of patients. Emerging studies have demonstrated that the gut-brain axis mediates IBD-induced mood disorders, but the underlying mechanisms of these findings remain unknown. This study unveiled promising evidence that choline dysfunction may be a cause of IBD induced mood disorders. Analysing Dextran Sulfate Sodium Salt (DSS)-induced IBD mice model with transcriptomics and metabolomics technology, it was discovered that mRNA responsible for acetylcholine synthesis and secretion were increased and the phosphatidylcholine (PC) content were decreased in prefrontal cortex (PFC) of IBD mice compared to the Control. Fecal Metagenomics showed that the microbiome and lipid metabolism were also abnormal in IBD mice. Since both acetylcholine and PC are choline metabolites, we inferred that the IBD mice may suffer from choline deficiency and choline metabolism disorder. Following supplementation of CDP-choline, experimental subjects showed improvements through decreased anxiety-like behaviors, reduced PC degradation and increased acetylcholine synthesis in the PFC. In addition, CDP-choline treatment was shown to restore the gut microbiome and lipid metabolism disorders characteristic of DSS treatment. This study provides compelling evidence to suggest that choline metabolism plays a key role in the development and treatment of mood disorders in IBD patients, and choline and its metabolites may play a key role in maintaining the stability of the gut-brain axis.
- Open Access
- 18 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8295580
Electroacupuncture Attenuated Anxiety and Depression‐Like Behavior via Inhibition of Hippocampal Inflammatory Response and Metabolic Disorders in TNBS‐Induced IBD Rats
This study was designed to explore the potential mechanisms of electroacupuncture (EA) in treating inflammatory bowel disease‐ (IBD‐) related anxiety and mood disorders. A colitis model was induced in rats with 2, 4, 6‐trinitrohydrosulfonic acid (TNBS), followed by ST36 and SP6 targeted therapy by EA or sham EA treatment. The elevated plus maze (EPM) and open‐field test (OFT) were performed to assess the state of anxiety and depression‐like behavior. Tests were carried out by 16S rDNA amplification sequence, 1H nuclear magnetic resonance (1H NMR) spectroscopy, immunofluorescence staining, and enzyme‐linked immunosorbent assay (ELISA). The analyses detailed metabolic alterations and the Toll‐like receptor 4 (TLR4) signaling pathway/NOD‐like receptor protein 3 (NLRP3) inflammasome in rats’ hippocampal region. Furthermore, the activity of the hypothalamic‐pituitary adrenal (HPA) axis and gut microbiome was assessed. As a result of treatment, EA significantly improved in the behavioral tests and altered the composition of the gut microbiome through a significant increase in the density of short chain fatty acids (SCFAs) producers mainly including Ruminococcaceae, Phascolarctobacterium, and Akkermansiaceae. EA upregulated the metabolites of the hippocampus mainly containing l‐glutamine and gamma‐aminobutyric acid (GABA), as well as ZO‐1 expression. Whereas the treatment blocked the TLR4/nuclear factor‐ kappa B (NF‐κB) signaling pathways and NLRP3 inflammasomes, along with downregulating the interleukin‐ (IL‐) 1β level. The hyperactivity of the HPA axis was also diminished. In conclusion, EA at ST36 and SP6 attenuated anxiety and depression‐like behavior in colitis model rats through their effects on the gut microbiome by modulating the hippocampal inflammatory response and metabolic disorders, as well as the HPA axis. This study provides evidence for clinical application of EA to serve as an adjunctive treatment for IBD‐related anxiety and depression.
- 18 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8295580
Open AccessElectroacupuncture Attenuated Anxiety and Depression‐Like Behavior via Inhibition of Hippocampal Inflammatory Response and Metabolic Disorders in TNBS‐Induced IBD Rats
This study was designed to explore the potential mechanisms of electroacupuncture (EA) in treating inflammatory bowel disease‐ (IBD‐) related anxiety and mood disorders. A colitis model was induced in rats with 2, 4, 6‐trinitrohydrosulfonic acid (TNBS), followed by ST36 and SP6 targeted therapy by EA or sham EA treatment. The elevated plus maze (EPM) and open‐field test (OFT) were performed to assess the state of anxiety and depression‐like behavior. Tests were carried out by 16S rDNA amplification sequence, 1H nuclear magnetic resonance (1H NMR) spectroscopy, immunofluorescence staining, and enzyme‐linked immunosorbent assay (ELISA). The analyses detailed metabolic alterations and the Toll‐like receptor 4 (TLR4) signaling pathway/NOD‐like receptor protein 3 (NLRP3) inflammasome in rats’ hippocampal region. Furthermore, the activity of the hypothalamic‐pituitary adrenal (HPA) axis and gut microbiome was assessed. As a result of treatment, EA significantly improved in the behavioral tests and altered the composition of the gut microbiome through a significant increase in the density of short chain fatty acids (SCFAs) producers mainly including Ruminococcaceae, Phascolarctobacterium, and Akkermansiaceae. EA upregulated the metabolites of the hippocampus mainly containing l‐glutamine and gamma‐aminobutyric acid (GABA), as well as ZO‐1 expression. Whereas the treatment blocked the TLR4/nuclear factor‐ kappa B (NF‐κB) signaling pathways and NLRP3 inflammasomes, along with downregulating the interleukin‐ (IL‐) 1β level. The hyperactivity of the HPA axis was also diminished. In conclusion, EA at ST36 and SP6 attenuated anxiety and depression‐like behavior in colitis model rats through their effects on the gut microbiome by modulating the hippocampal inflammatory response and metabolic disorders, as well as the HPA axis. This study provides evidence for clinical application of EA to serve as an adjunctive treatment for IBD‐related anxiety and depression.
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6244757
Curcumin Alleviates DSS‐Induced Anxiety‐Like Behaviors via the Microbial‐Brain‐Gut Axis
The anxiety and depression caused by inflammatory bowel diseases (IBD) are known to greatly affect the mental health of patients. The mechanism of psychiatric disorders caused by IBD is not fully understood. Previous research has suggested that the gut microbiome plays a key role in IBD. Curcumin is a yellow polyphenol extracted from the rhizome of the ginger plant, which has been shown to have effects against both depression and anxiety. Research has indicated that curcumin affects the gut microbiome and exerts antianxiety and neuroprotective effects through the microbiota‐gut‐brain axis (MGB). However, whether curcumin can alleviate the psychiatric disorders caused by IBD and how curcumin affects the MGB axis through the gut microbiota have not been fully understood. Therefore, this study was aimed at determining the metabolic parameters and microbiological environment in the peripheral and central nervous system to determine the effects of curcumin against anxiety induced by dextran sulfate sodium salt (DSS) in mice. To elaborate on the link between the gut microbiota and how curcumin alleviates anxiety‐like behaviors, we performed a fecal microbiota transplantation (FMT) experiment. The results suggested that curcumin can effectively relieve anxiety‐like behaviors caused by DSS in mice. Further, curcumin treatment can alleviate disturbances in the gut microbiota and systemic disorders of lipid metabolism caused by DSS. Finally, through FMT, we verified that curcumin increased phosphatidylcholine in the prefrontal cortex of the mice and alleviated DSS‐induced anxiety‐like behaviors by modulating specific gut microbiota. We also revealed that Muribaculaceae may be a key part of the gut microbiota for curcumin to alleviate DSS‐induced anxiety‐like behaviors through the MGB axis.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6244757
Open AccessCurcumin Alleviates DSS‐Induced Anxiety‐Like Behaviors via the Microbial‐Brain‐Gut Axis
The anxiety and depression caused by inflammatory bowel diseases (IBD) are known to greatly affect the mental health of patients. The mechanism of psychiatric disorders caused by IBD is not fully understood. Previous research has suggested that the gut microbiome plays a key role in IBD. Curcumin is a yellow polyphenol extracted from the rhizome of the ginger plant, which has been shown to have effects against both depression and anxiety. Research has indicated that curcumin affects the gut microbiome and exerts antianxiety and neuroprotective effects through the microbiota‐gut‐brain axis (MGB). However, whether curcumin can alleviate the psychiatric disorders caused by IBD and how curcumin affects the MGB axis through the gut microbiota have not been fully understood. Therefore, this study was aimed at determining the metabolic parameters and microbiological environment in the peripheral and central nervous system to determine the effects of curcumin against anxiety induced by dextran sulfate sodium salt (DSS) in mice. To elaborate on the link between the gut microbiota and how curcumin alleviates anxiety‐like behaviors, we performed a fecal microbiota transplantation (FMT) experiment. The results suggested that curcumin can effectively relieve anxiety‐like behaviors caused by DSS in mice. Further, curcumin treatment can alleviate disturbances in the gut microbiota and systemic disorders of lipid metabolism caused by DSS. Finally, through FMT, we verified that curcumin increased phosphatidylcholine in the prefrontal cortex of the mice and alleviated DSS‐induced anxiety‐like behaviors by modulating specific gut microbiota. We also revealed that Muribaculaceae may be a key part of the gut microbiota for curcumin to alleviate DSS‐induced anxiety‐like behaviors through the MGB axis.